Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 4/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | FAP | Q12884 | 2/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9285831 | 0.86 | MEN1 (0.43) | SLC6A9ROCK2SCDSCD5 | |
| SCHEMBL840847 | 0.85 | RIPK1 (0.51) | SLC6A9CES2CES1ADAM17 | |
| SCHEMBL840944 | 0.83 | TRPM8 (0.46) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL839780 | 0.83 | SLC6A9 (0.42) | SLC6A9TRPM8ROCK2SCDSCD5 | |
| SCHEMBL859083 | 0.83 | TRPM8 (0.46) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL839785 | 0.83 | DPP4 (0.46) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL840848 | 0.83 | DPP4 (0.40) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL839041 | 0.80 | SLC6A9 (0.38) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL840618 | 0.79 | RAB9A (0.39) | SLC6A9DPP4FAPDPP8DPP9 | |
| SCHEMBL840505 | 0.79 | OPRD1 (0.55) | SLC6A9DPP4FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-8324217-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-8324217-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-05-31 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143259-B2 | Cold menthol receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2012-03-27 | — | — | US | disclosed |
| EP-2331499-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | SLC6A9 3926/4885CES2 997/4885CES1 1074/4885 |
| US-20120136006-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | TRPV1, TRPM2, TRPM6 | SLC6A9 3926/4885CES2 997/4885CES1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.